Lexicon Pharmaceuticals | LXRX - Cost Of Sales


Lexicon Pharmaceuticals reported $201K in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Illumina USD 370M 30M Mar/2026
Insmed USD 49.5M 3.34M Mar/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
J&J USD 8.07B 103M Mar/2026
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
MacroGenics USD 9.53M 585K Mar/2026
MannKind USD 39.58M 5.94M Mar/2026
Merck USD 2.94B 380M Mar/2026
Moderna USD 955M 503M Mar/2026
Novartis USD 3.46B 83M Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Thermo Fisher Scientific USD 6.96B 620M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
United Therapeutics USD 133.4M 341.3M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024